StreetInsider.com News Articles

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:

Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Thu, 26 Feb 2026 15:34:00 -0400

Highlights:
First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS
Approximately 160 participants with ALS will be enrolled in a 36-week randomised, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial in leading ALS clinical centres across the United States
Follows a successful Phase 1 clinical program in a small study population (n=12) in people living with ALS, which showed encouraging preliminary signals of efficacy and NUZ-001 was safe and well-tolerated
Study is expected to complete enrolment in H2 CY2026
MELBOURNE, Australia, Feb. 26, 2026 /PRNewswire/